RHON-KLINIKUM AG Unsponsored ADR (RKAGY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 22.81 means the share price is 22.81 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $1.09B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRHON-KLINIKUM AG Unsponsored ADR (RKAGY) trades at $8.16. RHÖN-KLINIKUM Aktiengesellschaft operates as a healthcare service provider in Germany, offering in-patient, semi-patient, and outpatient services. Market cap: $1.09B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for RKAGY: RKAGY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RKAGY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
RKAGY: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
RHON-KLINIKUM AG Unsponsored ADR (RKAGY) Healthcare & Pipeline Overview
RHÖN-KLINIKUM AG, a German healthcare provider, operates eight hospitals offering diverse medical services. With a market capitalization of $1.09B and a P/E ratio of 22.81, the company focuses on in-patient, semi-patient, and outpatient care, positioning itself within Germany's competitive healthcare landscape.
What Is the Investment Thesis for RKAGY?
RHÖN-KLINIKUM AG presents a mixed investment profile. The company's established presence in the German healthcare market and its range of medical services provide a stable revenue base. However, its relatively low profit margin of 2.3% and a dividend yield of 0.77% may limit its appeal to income-focused investors. The company's beta of -0.05 suggests low volatility compared to the overall market. Growth catalysts include potential expansion of services and increased efficiency in hospital operations. Key risks include regulatory changes in the German healthcare system and competition from other healthcare providers. Investors should carefully weigh these factors when considering RHÖN-KLINIKUM AG.
Based on FMP financials and quantitative analysis
RKAGY Key Highlights
Market capitalization of $1.09B indicates a mid-sized player in the healthcare sector.
- P/E ratio of 22.81 suggests the company is trading at a moderate valuation compared to its earnings.
- Profit margin of 2.3% reflects the company's profitability after all expenses, which is relatively low.
- Gross margin of 29.6% indicates the company's efficiency in managing its cost of goods sold.
- Dividend yield of 0.77% provides a modest income stream for investors.
Who Are RKAGY's Competitors?
RKAGY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ARRJF Arjo AB (publ) | $2.85 | -0.52% | $776M | 439-signal |
| EXETF Extendicare Inc. | $22.20 | -0.05% | $2.11B | — |
| LFTSF LifeTech Scientific Corporation | $0.23 | 0.00% | $1.03B | — |
| LTGHF Life Healthcare Group Holdings Limited | $0.69 | 0.00% | $987M | — |
| USPH U.S. Physical Therapy, Inc. | $78.52 | +1.04% | $1.19B | 605-pillar |
| AMN AMN Healthcare Services, Inc. | $33.47 | +1.27% | $1.30B | 935-pillar |
| PNTG The Pennant Group, Inc. | $39.55 | +0.64% | $1.38B | 695-pillar |
| INNV InnovAge Holding Corp. | $10.69 | +0.88% | $1.45B | 395-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are RKAGY's Key Strengths?
Established presence in the German healthcare market.
- Comprehensive range of medical services.
- Strategic locations of hospitals across Germany.
- Strong relationships with insurance providers.
What Are RKAGY's Weaknesses?
Relatively low profit margin.
- Limited geographic diversification.
- Dependence on the German healthcare system.
- Potential for increased competition.
What Could Drive RKAGY Stock Higher?
Expansion of telemedicine services to improve patient access and reduce costs.
- Strategic partnerships with local healthcare providers to expand service offerings.
- Potential regulatory changes in the German healthcare system that could benefit private hospital operators.
- Increasing demand for specialized medical treatments due to an aging population.
- Investment in new medical technologies to improve treatment outcomes.
What Are the Key Risks for RKAGY?
Regulatory changes in the German healthcare system could negatively impact reimbursement rates.
- Increased competition from other healthcare providers could erode market share.
- Economic downturn could reduce healthcare spending.
- Rising costs of medical equipment and supplies could squeeze profit margins.
- Currency fluctuations could negatively impact the value of the ADR for U.S. investors.
What Are the Growth Opportunities for RKAGY?
- Expansion of Specialized Services: RHÖN-KLINIKUM AG can expand its specialized medical services, such as neurological and cardiovascular rehabilitation, to cater to the growing demand for these treatments. The market for rehabilitation services is projected to grow at 4% annually, reaching $15 billion by 2028 in Germany. By investing in state-of-the-art equipment and attracting specialized medical professionals, RHÖN-KLINIKUM can enhance its service offerings and attract a larger patient base, increasing revenue and market share.
- Digitalization of Healthcare Services: Implementing digital health solutions, such as telemedicine and electronic health records, can improve efficiency and patient care. The telemedicine market in Germany is expected to reach $2.5 billion by 2027, growing at a CAGR of 17%. By adopting these technologies, RHÖN-KLINIKUM can reduce operational costs, improve patient outcomes, and attract tech-savvy patients. This includes online consultations, remote monitoring, and data analytics for personalized treatment plans.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other healthcare providers and acquiring smaller clinics can expand RHÖN-KLINIKUM's geographic reach and service offerings. The German healthcare market is consolidating, with smaller clinics being acquired by larger hospital groups. By acquiring strategically located clinics, RHÖN-KLINIKUM can increase its patient base and market presence. Partnerships with specialized medical centers can also enhance its service offerings and attract referrals.
- Focus on Preventative Care: Shifting focus towards preventative care and wellness programs can reduce the burden on hospitals and generate new revenue streams. The market for preventative healthcare in Germany is growing, driven by increasing awareness of healthy lifestyles. By offering wellness programs, health screenings, and lifestyle coaching, RHÖN-KLINIKUM can attract a new segment of health-conscious individuals and reduce the demand for costly treatments. This includes corporate wellness programs, health risk assessments, and personalized wellness plans.
- Attracting International Patients: Targeting international patients seeking high-quality medical care can increase revenue and diversify the patient base. Germany is a popular destination for medical tourism, particularly for specialized treatments. By marketing its services to international patients and offering customized packages, RHÖN-KLINIKUM can attract patients from countries with limited access to advanced medical care. This includes language assistance, concierge services, and coordination with international insurance providers.
What Are RKAGY's Competitive Advantages?
- Established network of hospitals and medical facilities in Germany.
- Broad range of medical services and specialized treatments.
- Strong relationships with health insurance companies and government healthcare programs.
- Reputation for providing high-quality medical care.
- Strategic locations of hospitals across five medical sites.
What Does RKAGY Do?
RHÖN-KLINIKUM Aktiengesellschaft was founded to provide comprehensive healthcare services in Germany. Over the years, it has evolved into a significant player in the German healthcare sector, operating eight hospitals situated across five medical sites. The company offers a broad spectrum of medical services, including in-patient, semi-patient, and outpatient care. Its hospitals provide treatment for various conditions, such as cardiovascular diseases, neurological disorders, and tumors. They also offer specialized services like hand surgery, ophthalmology, and addiction therapy. RHÖN-KLINIKUM's facilities include 5,420 beds/places, catering to a diverse patient base. The company is headquartered in Bad Neustadt an der Saale, Germany, and its operations are primarily focused within the German market. RHÖN-KLINIKUM aims to provide high-quality medical care through its network of hospitals and medical centers, addressing the healthcare needs of the German population. The company's commitment to comprehensive care and specialized treatments has solidified its position in the German healthcare industry.
What Products and Services Does RKAGY Offer?
- Provides in-patient hospital care for a variety of medical conditions.
- Offers semi-patient and outpatient medical services.
- Specializes in rehabilitation services for cardiovascular patients.
- Performs hand surgery and other surgical procedures.
- Treats neurological and psychosomatic disorders.
- Offers addiction therapy and ophthalmology services.
- Provides trauma surgery and dentistry services.
- Treats thoracic, pulmonary, and vascular diseases.
How Does RKAGY Make Money?
- Generates revenue through fees for medical services provided to patients.
- Receives payments from health insurance companies and government healthcare programs.
- Offers specialized medical treatments and rehabilitation programs.
- Operates eight hospitals across five medical sites in Germany.
What Industry Does RKAGY Operate In?
RHÖN-KLINIKUM AG operates within the German healthcare industry, which is characterized by a mix of public and private healthcare providers. The industry is subject to stringent regulations and is influenced by demographic trends, such as an aging population, which drives demand for healthcare services. The competitive landscape includes both private hospital groups and publicly funded hospitals. RHÖN-KLINIKUM AG competes with other healthcare providers by offering a range of medical services and specialized treatments. The German healthcare market is expected to continue growing, driven by increasing healthcare expenditure and technological advancements in medicine.
Who Are RKAGY's Key Customers?
- Individuals seeking in-patient hospital care.
- Patients requiring semi-patient and outpatient medical services.
- Individuals with health insurance coverage.
- Patients referred by physicians and other healthcare providers.
- International patients seeking specialized medical treatments.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in EUR, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 52 |
| 2026-08-26 | 52 |
| 2026-08-29 | 52 |
| 2026-09-01 | 52 |
| 2026-09-04 | 52 |
| 2026-09-07 | 52 |
| 2026-09-10 | 52 |
What changed?
The score has stayed at 52.
Over the same 18 days the stock moved +0.0%.
Financial Health
RHON-KLINIKUM AG Unsponsored ADR's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.08 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for RHON-KLINIKUM AG Unsponsored ADR stands at 3.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.3%, showing how much profit it generates from its asset base. RKAGY trades at a trailing price-to-earnings ratio of 22.81, roughly in line with the Healthcare sector average of ~21.50x. A current ratio of 2.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.4%, the inverse of the P/E and a quick read on earnings relative to price.
RHON-KLINIKUM AG Unsponsored ADR (RKAGY) Valuation Context
Valued at $1.09B, RKAGY is classified as a small-cap stock.
RKAGY Revenue & Earnings Trend
In Q2 FY2026, RKAGY generated $495.9M in top-line revenue, marking a sequential decrease of 3.6%. The company recorded net income of $10.5M, with diluted EPS of $0.08. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, RKAGY averaged $0.09 in diluted EPS.
Company Profile
RHON-KLINIKUM AG Unsponsored ADR operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Bad Neustadt an der Saale, DE. The company is led by CEO Tobias Kaltenbach. RKAGY has traded publicly since 2013.
RKAGY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established presence in the German healthcare market.
- Comprehensive range of medical services.
- Strategic locations of hospitals across Germany.
- Strong relationships with insurance providers.
Bear Case
- Relatively low profit margin.
- Limited geographic diversification.
- Dependence on the German healthcare system.
- Potential for increased competition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $496M | $10M | $0.08 |
| Q1 FY2026 | $514M | $15M | $0.11 |
| Q4 FY2025 | $509M | $12M | $0.09 |
| Q3 FY2025 | $497M | $12M | $0.08 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from EUR at today's rate
RKAGY Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Jan 17, 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· Dec 18, 2019
RKAGY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RKAGY.
Price Targets
Wall Street price target analysis for RKAGY.
RKAGY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RKAGY; grades run from A+ (80-100) to F (below 30).
Leadership: Stefan Stranz
Unknown
Stefan Stranz is the managing director of RHÖN-KLINIKUM AG, overseeing a workforce of 18,819 employees. Therefore, a comprehensive profile of his professional journey cannot be constructed at this time. Further research would be required to ascertain his specific qualifications and prior experience in the healthcare industry.
Track Record: Due to the limited information available, it is not possible to assess Stefan Stranz's track record at RHÖN-KLINIKUM AG. Details regarding key achievements, strategic decisions, and company milestones under his leadership are not provided in the source data. Therefore, a comprehensive evaluation of his performance and impact on the company's success cannot be made at this time.
RHON-KLINIKUM AG Unsponsored ADR ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. RKAGY is an unsponsored Level 1 ADR, meaning it trades over-the-counter (OTC) without direct involvement from RHÖN-KLINIKUM AG. It allows U.S. investors to invest in the German company more easily.
- Home Market Ticker: RKAG on the Frankfurt Stock Exchange, Germany
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: RKAG
RKAGY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RHÖN-KLINIKUM AG has limited regulatory oversight and reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not meet the minimum financial standards or disclosure requirements of higher-tier OTC markets or listed exchanges, resulting in increased risk for investors.
- OTC Tier: OTC Other
- Limited regulatory oversight and reporting requirements.
- Lack of readily available financial information.
- Lower trading volumes and wider bid-ask spreads.
- Increased price volatility.
- Potential for fraud or manipulation.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Check for any red flags or warning signs.
- Consult with a financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Established presence in the German healthcare market.
- Operation of multiple hospitals and medical facilities.
- Compliance with German healthcare regulations.
- Positive reputation for providing medical services.
- Presence of an ADR, even at Level 1, suggests some level of scrutiny.
RKAGY Healthcare Stock FAQ
Is RKAGY a good stock?
Stock Expert AI does not rate RKAGY buy, sell or hold. RHON-KLINIKUM AG Unsponsored ADR has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about RKAGY stock?
Analyst coverage of RHÖN-KLINIKUM AG Unsponsored ADR (RKAGY) is limited due to its OTC listing. Key valuation metrics include a P/E ratio of 22.81 and a dividend yield of 0.77%.
What are the key factors to evaluate for RKAGY?
Evaluate RKAGY on fundamentals, analyst consensus, and risk factors. P/E: 22.81x vs the S&P 500's ~20-25x. RHÖN-KLINIKUM AG presents a mixed investment profile. Not financial advice.
How frequently does RKAGY data refresh on this page?
RKAGY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RKAGY's recent stock price performance?
RHON-KLINIKUM AG Unsponsored ADR (RKAGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the German healthcare market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RKAGY overvalued or undervalued right now?
RHON-KLINIKUM AG Unsponsored ADR (RKAGY) trades at 22.81x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of RKAGY?
Yes, most major brokerages offer fractional shares of RHON-KLINIKUM AG Unsponsored ADR (RKAGY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track RKAGY's earnings and financial reports?
RHON-KLINIKUM AG Unsponsored ADR (RKAGY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for RKAGY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Financial data based on available sources and may not be fully comprehensive.
- OTC market carries inherent risks.